Literature DB >> 10319139

Comparative studies of adriamycin and 28-deacetyl sendanin on in vitro growth inhibition of human cancer cell lines.

H M Kim1, G T Oh, S B Han, D H Hong, B Y Hwang, Y H Kim, J J Lee.   

Abstract

The limonoid compound (28-deacetyl sendanin) isolated from the fruit of Melia toosendan SIEB. et ZUCC. was evaluated on anticancer activity. According to a standard in vitro cytotoxicity assay, eight human cancer cell lines and SRB assay were introduced for present evaluation. As a positive standard, adriamycin was tested in parallel. The cell lines were originated from six different organs. In view of dose-response profiles to 28-deacetyl sendanin, the most sensitive cells were SF-539 and PC-3 which were derived from CNS and prostate, respectively. In contrast, all the cell lines responded similarly to adriamycin to give rise to nearly identical dose-response profiles. By comparison of Gl50 between 28-deacetyl sendanin and adriamycin, six cell lines were more sensitive to 28-deacetyl sendanin and two were more resistant. As a result, 28-deacetyl sendanin had more sensitive and selective inhibitory effects on in vitro growth of human cancer cell lines in a comparison with adriamycin.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 10319139     DOI: 10.1007/bf02974231

Source DB:  PubMed          Journal:  Arch Pharm Res        ISSN: 0253-6269            Impact factor:   4.946


  6 in total

1.  A simplified method of evaluating dose-effect experiments.

Authors:  J T LITCHFIELD; F WILCOXON
Journal:  J Pharmacol Exp Ther       Date:  1949-06       Impact factor: 4.030

2.  Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines.

Authors:  A Monks; D Scudiero; P Skehan; R Shoemaker; K Paull; D Vistica; C Hose; J Langley; P Cronise; A Vaigro-Wolff
Journal:  J Natl Cancer Inst       Date:  1991-06-05       Impact factor: 13.506

3.  New colorimetric cytotoxicity assay for anticancer-drug screening.

Authors:  P Skehan; R Storeng; D Scudiero; A Monks; J McMahon; D Vistica; J T Warren; H Bokesch; S Kenney; M R Boyd
Journal:  J Natl Cancer Inst       Date:  1990-07-04       Impact factor: 13.506

4.  Multidrug-resistant phenotype of disease-oriented panels of human tumor cell lines used for anticancer drug screening.

Authors:  L Wu; A M Smythe; S F Stinson; L A Mullendore; A Monks; D A Scudiero; K D Paull; A D Koutsoukos; L V Rubinstein; M R Boyd
Journal:  Cancer Res       Date:  1992-06-01       Impact factor: 12.701

5.  Evaluation of limonoids against the murine P388 lymphocytic leukemia cell line.

Authors:  G R Pettit; D H Barton; C L Herald; J Polonsky; J M Schmidt; J D Connolly
Journal:  J Nat Prod       Date:  1983 May-Jun       Impact factor: 4.050

6.  Chemosensitivity testing of human colorectal carcinoma cell lines using a tetrazolium-based colorimetric assay.

Authors:  J G Park; B S Kramer; S M Steinberg; J Carmichael; J M Collins; J D Minna; A F Gazdar
Journal:  Cancer Res       Date:  1987-11-15       Impact factor: 12.701

  6 in total
  3 in total

1.  Growth inhibition and apoptosis-induced effect on human cancer cells of toosendanin, a triterpenoid derivative from chinese traditional medicine.

Authors:  Bin Zhang; Zhong-Feng Wang; Mian-Zhi Tang; Yu-Liang Shi
Journal:  Invest New Drugs       Date:  2005-12       Impact factor: 3.850

2.  Identification and Verification of Potential Biomarkers in Gastric Cancer By Integrated Bioinformatic Analysis.

Authors:  Chenyu Sun; Yue Chen; Na Hyun Kim; Scott Lowe; Shaodi Ma; Zhen Zhou; Rachel Bentley; Yi-Sheng Chen; Margarita Whitaker Tuason; Wenchao Gu; Chandur Bhan; John Pocholo Whitaker Tuason; Pratikshya Thapa; Ce Cheng; Qin Zhou; Yanzhe Zhu
Journal:  Front Genet       Date:  2022-07-15       Impact factor: 4.772

3.  Pregnane Steroids from the Leaves of Melia Azedarach and Apoptotic Activity against T47D Cells.

Authors:  Martha Ervina; Hadi Poerwono; Retno Widyowati; Hideaki Otsuka; Katsuyoshi Matsunami; Sukardiman Sukardiman
Journal:  Asian Pac J Cancer Prev       Date:  2021-06-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.